Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
$10.50
$10.46
$2.00
$10.50
$231.40M-4.81142,261 shsN/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$7.77
-19.6%
$10.15
$3.60
$11.99
$107.43M0.4442,826 shs32,633 shs
INmune Bio, Inc. stock logo
INMB
INmune Bio
$2.61
+10.4%
$6.98
$1.89
$11.64
$61.43M1.34778,332 shs4.70 million shs
BiomX Inc. stock logo
PHGE
BiomX
$0.45
-39.4%
$0.50
$0.34
$3.86
$12.54M1.43106,529 shs53,300 shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$1.97
-0.8%
$3.19
$1.81
$26.96
$11.38M0.54133,066 shs380,089 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-0.83%+6.66%+20.00%+3.46%+53.25%
INmune Bio, Inc. stock logo
INMB
INmune Bio
+10.38%-58.52%-64.17%-64.17%-67.40%
BiomX Inc. stock logo
PHGE
BiomX
+2.05%-2.18%-10.93%-21.27%-87.05%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-0.76%-1.75%-50.38%-69.48%-88.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
4.3575 of 5 stars
3.53.00.04.40.62.51.3
INmune Bio, Inc. stock logo
INMB
INmune Bio
1.6336 of 5 stars
3.30.00.00.02.01.70.6
BiomX Inc. stock logo
PHGE
BiomX
N/AN/AN/AN/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
4.7194 of 5 stars
3.52.00.04.61.13.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
0.00
N/AN/AN/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
3.00
Buy$12.0054.44% Upside
INmune Bio, Inc. stock logo
INMB
INmune Bio
2.57
Moderate Buy$18.40606.33% Upside
BiomX Inc. stock logo
PHGE
BiomX
3.00
Buy$21.004,587.50% Upside
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.00
Buy$72.333,581.09% Upside

Current Analyst Ratings Breakdown

Latest CSBR, PHGE, CMPI, XFOR, and INMB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $8.00
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Outperform ➝ Sector Underperform
6/30/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
5/16/2025
BiomX Inc. stock logo
PHGE
BiomX
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/2/2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1.50 ➝ $7.00
4/4/2025
BiomX Inc. stock logo
PHGE
BiomX
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/AN/AN/AN/A$2.50 per shareN/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$50.15M2.14N/AN/A($0.14) per share-55.50
INmune Bio, Inc. stock logo
INMB
INmune Bio
$10K6,142.59N/AN/A$1.45 per share1.80
BiomX Inc. stock logo
PHGE
BiomX
N/AN/AN/AN/A$0.70 per shareN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$2.56M4.44N/AN/A$3.90 per share0.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
-$61.40M-$2.92N/AN/AN/AN/A-83.92%-74.99%N/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$7.28M-$0.0617.66N/A10.97%656.65%24.04%N/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)
BiomX Inc. stock logo
PHGE
BiomX
-$28.32M-$0.85N/AN/AN/AN/A-127.82%-56.50%N/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$37.45M$2.140.92N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)

Latest CSBR, PHGE, CMPI, XFOR, and INMB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.43-$0.43N/A-$0.43N/A$0.05 million
5/1/2025Q1 2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$4.13$0.04+$4.17$0.04$7.03 million$28.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/AN/AN/AN/AN/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/AN/AN/AN/AN/A
BiomX Inc. stock logo
PHGE
BiomX
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/A
5.20
5.20
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/A
0.99
0.99
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/A
2.64
2.64
BiomX Inc. stock logo
PHGE
BiomX
0.51
2.84
2.84
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.30
3.70
3.58

Institutional Ownership

CompanyInstitutional Ownership
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
74.56%
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
41.30%
INmune Bio, Inc. stock logo
INMB
INmune Bio
12.72%
BiomX Inc. stock logo
PHGE
BiomX
40.57%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
72.03%

Insider Ownership

CompanyInsider Ownership
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
62.60%
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
46.98%
INmune Bio, Inc. stock logo
INMB
INmune Bio
35.70%
BiomX Inc. stock logo
PHGE
BiomX
1.17%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
2.37%
CompanyEmployeesShares OutstandingFree FloatOptionable
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
2822.04 million8.24 millionNot Optionable
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
14313.83 million7.33 millionOptionable
INmune Bio, Inc. stock logo
INMB
INmune Bio
1023.58 million15.17 millionOptionable
BiomX Inc. stock logo
PHGE
BiomX
12026.18 million44.04 millionNot Optionable
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
805.79 million5.65 millionOptionable

Recent News About These Companies

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance
X4 Pharmaceuticals Inc News (XFOR) - Investing.com
XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha
X4 Pharmaceuticals Analyst Ratings
Earnings Preview For X4 Pharmaceuticals
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Checkmate Pharmaceuticals stock logo

Checkmate Pharmaceuticals NASDAQ:CMPI

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Champions Oncology stock logo

Champions Oncology NASDAQ:CSBR

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

INmune Bio stock logo

INmune Bio NASDAQ:INMB

$2.60 +0.25 (+10.38%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$2.55 -0.06 (-2.11%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

BiomX stock logo

BiomX NYSEMKT:PHGE

$0.45 -0.29 (-39.38%)
Closing price 07/3/2025 03:45 PM Eastern
Extended Trading
$0.44 -0.01 (-1.79%)
As of 07/3/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

X4 Pharmaceuticals stock logo

X4 Pharmaceuticals NASDAQ:XFOR

$1.96 -0.02 (-0.76%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$1.92 -0.05 (-2.29%)
As of 07/3/2025 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.